Clinical trialNCT02091245Active, not recruitingPhase 1Interventional

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

SponsorDana-Farber Cancer InstituteEnrollment16Chronic Myelogenous Leukemia (CML) in Blast CrisisRefractory Acute Lymphoblastic Leukemia (ALL)Refractory Acute Myelogenous Leukemia (AML)Refractory Biphenotypic LeukemiaRefractory Mixed Lineage LeukemiaRelapsed Acute Lymphoblastic Leukemia (ALL)+3 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study involves participants who have acute lymphoblastic or acute myelogenous leukemia that has relapsed or has become resistant (or refractory) to standard therapies. This research study is evaluating a drug called KPT-330. Laboratory and other studies suggest that the study drug, KPT-330, may prevent leukemia cells from growing and may lead to the destruction of leukemia cells. It is thought that KPT-330 activates cellular processes that increase the death of leukemia cells. The main goal of this study is to evaluate the side effects of KPT-330 when it is administered to children and adolescents with relapsed or refractory leukemia.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Andrew E Place, MD,PhD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Ucsf
San Francisco, California, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Children'S Healthcare of Atlanta
Atlanta, Georgia, United States
Boston Children'S Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Columbia University Medical Center
New York, New York, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Texas Children'S Hospital
Houston, Texas, United States
Seattle Children'S Hospital
Seattle, Washington, United States
Children'S Hospital of Wisconsin
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

KPT-330

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2014
Primary completion: 28 Feb 2018
Completion: 31 Dec 2026
Last update posted: 29 May 2026
Registered enrollment: 16
Registry id: NCT02091245

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.